Anticonvulsants in anxiety disorders

Current Psychiatry Reports

Volumn 7, Issue 4, 2005, Pages 258-267

  Kinrys, Gustavo ^a   Wygant, Lisa E ^b  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; ETIRACETAM; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; LORAZEPAM; OXCARBAZEPINE; PAROXETINE; PHENYTOIN; PLACEBO; PREGABALIN; QUETIAPINE; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; VIGABATRIN;

ANXIETY DISORDER; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; ELECTROENCEPHALOGRAPHY; GENERALIZED ANXIETY DISORDER; HUMAN; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PANIC; POSTTRAUMATIC STRESS DISORDER; RATING SCALE; REVIEW; SCORING SYSTEM; SOCIAL PHOBIA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 24944463415     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-005-0079-3     Document Type: Review

References (74)

1. Pope Jr HG, McElroy SL, Keck Jr PE, et al.: Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991, 48:62-68.
2. Lerer B, Moore N, Meyendorff E, et al.: Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987, 48:89-93.
3. Clark RD, Canive JM, Calais LA, et al.: Divalproex in post-traumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999, 12:395-401.
4. Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999, 19:341-348.
5. Kinrys G, Pollack MH, Simon NM, et al.: Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003, 18:169-172.
6. Stahl SM: Symptoms and circuits, part 2: anxiety disorders. J Clin Psychiatry 2003, 64:1408-1409.
7. Stahl SM: Psychopharmacology of anticonvulsants: do all anticonvulsants have the same mechanism of action? J Clin Psychiatry 2004, 65:149-150.
8. Rosenthal M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003, 64:1245-1249.
9. Gruener D: Tiagabine as an augmenting agent for the treatment of anxiety [poster]. Presented at the 22nd National Conference of the Anxiety Disorders Association of America. Austin, Mar 21-24, 2002.
10. Papp LA, Ray S: Tiagabine treatment of generalized anxiety disorder [poster]. Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco, May 17-22, 2003.
11. Van Ameringen M, Pollack MH, Roy-Byrne PP: A randomized, double-blind, placebo-controlled study of tiagabine in patients with generalized anxiety disorder [poster]. Presented at the 24th Collegium Internationale Neuro-Psychopharmacologicium (CINP) Congress. Paris, June 20-24, 2004.
12. Pande AC, Crockatt JG, Feltner DE, et al.: Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003, 160:533-540.
13. Lydiard B, Bielski RJ, Zornber GL, et al.: Efficacy of pregabalin in treating psychic and somatic symptoms in generalized anxiety disorder (GAD) [poster]. Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco, May 17-22, 2003.
14. Montgomery SA, Rickels K, Belski RJ, et al.: Pregabalin in generalized anxiety disorder:speed of onset [poster]. Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco, May 17-22, 2003.
15. Pollack MH, Zimbroff DL, Tobias K, et al.: Pregabalin in generalized anxiety disorder analyses of subsyndromic depression [poster]. Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco, May 17-22, 2003.
16. Pollack MH, Matthews J, Scott EL: Gabapentin as a potential treatment for anxiety disorders [letter]. Am J Psychiatry 1998, 155:992-993.
17. Pollack M: Levetiracetam (Keppra) for anxiety. Curbside Consultant 2002, 1:4.
18. Nardi AE, Mendolwicz M, Versiani FM: Valproic add in social phobia: an open trial [abstract]. Biol Psychiatry 1997, 42:118S.
19. Kinrys G, Pollack MH, Simon NM, et al.: Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003, 18:169-172.
20. Pande AC, Davidson JR, Jefferson JW, et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999, 19:341-348.
21. Simon NM, Worthington JJ, Doyle AC, et al.: An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004, 65:1219-1222.
22. Van Ameringen M, Mancini C, Pipe B, et al.: An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004, 65:1674-1678.
23. Papp LA, Ninan PT: Tiagabine for the treatment of social anxiety disorder [abstract]. Presented at the 157th Annual Meeting of the American Psychiatric Association. New York, May 1-6, 2004.
24. Kinrys G, Soldani F, Hsu D, et al.: Adjunctive tiagabine for treatment refractory social anxiety disorder [poster]. Presented at the 157th Annual Meeting of the American Psychiatric Association. New York May 1-6, 2004.
25. Pande AC, Feltner DE, Jefferson JW, et al.: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004, 24:141-149.
26. Pande AC, Pollack MH, Crockatt J, et al.: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000, 20:467-471.
27. Zwanzger P, Baghai TC, Schule C, et al.: Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 2001, 62:656-657.
28. Gruener D: Tiagabine as an augmenting agent for the treatment of anxiety [poster]. Presented at the 2nd National Conference of the Anxiety Disorders Association of America. Austin, March 21-24, 2002.
29. Zwanzger P, Eser D, Padberg F, et al.: Effects of tiagabine treatment on cholecystokin-tetrapeptide (CCK-r) induced anxiety in healthy volunteers [abstract P.4.W.064]. Int J Neuropsychopharmacol 2002, 5(Suppl 1):S215.
30. Ontiveros A, Fontaine R: Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992, 17:78-80.
31. Woodman CL, Noyes Jr R: Panic disorder: treatment with valproate. J Clin Psychiatry 1994, 55:134-136.
32. Primeau F, Fontaine R, Beauclair L: Valproic acid and panic disorder. Can J Psychiatry 1990, 35:248-250.
33. Keck Jr PE, Taylor VE, Tugrul KC, et al.: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993, 33:542-546.
34. Baetz M, Bowen RC: Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can J Psychiatry 1998, 43:73-77.
35. Lum M, Fontaine R, Elie R, et al.: Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study [abstract]. Biol Psychiatry 1990, 27:164A.
36. Lawlor BA: Carbamazepine, alprazolam withdrawal, and panic disorder. Am J Psychiatry 1987, 144:265-266.
37. Tondo L, Burrai C, Scamonatti L, et al.: Carbamazepine in panic disorder. Am J Psychiatry 1989, 146:558-559.
38. Uhde TW, Stein MB, Post RM: Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988, 145:1104-1109.
39. McNamara ME, Fogel BS: Anticonvulsant-responsive panic attacks with temporal lobe EEG abnormalities. J Neuropsychiatry Clin Neurosci 1990, 2:193-196.
40. Zwanzger P, Baghai T, Boerner RJ, et al.: Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 2001, 21:539-540.
41. Bremner JD, Mletzko T, Welter S, et al.: Treatment of post-traumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry 2004, 65:1559-1564.
42. Taylor FB: Tiagabine for posttraumatic stress disorder: a case series of 7 women. J Clin Psychiatry 2003, 64:1421-1425.
43. Lara ME: Tiagabine for augmentation of antidepressant treatment of post-traumatic stress disorder [poster]. Presented at the 22nd National Conference of the Anxiety Disorders Association of America. Austin, March 21-24, 2002.
44. Berigan T: Treatment of posttraumatic stress disorder with tiagabine [letter]. Can J Psychiatry 2002, 47:788.
45. Davidson J, Weisler R, Connor K, et al.: Tiagabine for post-traumatic stress disorder: a placebo-controlled trial [poster]. Presented at the 24th Annual Conference of the Anxiety Disorders Association of America. Miami, March 11-14, 2004.
46. Brannon N, Labbate L, Huber M: Gabapentin treatment for posttraumatic stress disorder. Can J Psychiatry 2000, 45:84.
47. Hamner MB, Brodrick PS, Labbate LA: Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001, 13:141-146.
48. Szymanski HV, Olympia J: Divalproex in posttraumatic stress disorder. Am J Psychiatry 1991, 148:1086-1087.
49. Clark RD, Canive JM, Calais LA, Qualls CF, Tuason VB: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999, 12:395-401.
50. Fesler FA: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991, 52:361-364.
51. Petty F, Davis LL, Nugent AL, et al.: Valproate therapy for chronic, combat-induced posttraumatic stress disorder [letter]. J Clin Psychopharmol 2002, 22:100-102.
52. Otte C, Wiedemann K, Yassouridis A, et al.: Valproate monotherapy in the treatment of civilian patients with non-combat-related posttraumatic stress disorder: an open-label study [letter]. J Clin Psychopharmacol 2004, 24:106-108.
53. Goldberg JF, Cloitre M, Whiteside JE, Han H: An open-label pilot study of divalproex sodium for posttraumatic stress disorder related to childhood abuse. Curr Ther Res 2003, 64:45-54.
54. Hertzberg MA, Butterfield MI, Feldman ME, et al.: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999, 45:1226-1229.
55. Lipper S: PTSD and carbamazepine. Am J Psychiatry 1988, 145:1322-1323.
56. Wolf ME, Alavi A, Mosnaim AD: Posttraumatic stress disorder in Vietnam veterans clinical and EEG findings; possible therapeutic effects of carbamazepine. Biol Psychiatry 1988, 23:642-644.
57. Looff D, Grimley P, Kuller F, et al.: Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 1995, 34:703-704.
58. Macleod AD: Vigabatrin and posttraumatic stress disorder. J Clin Psychopharmacol 1996, 16:190-191.
59. Berlant J, van Kammen DP: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002, 63:15-20.
60. Berigan T: Oxcarbazepine treatment of posttraumatic stress disorder [letter]. Can J Psychiatry 2002, 47:973-974.
61. Kinrys G, Wygant LE, Pardo TB, Melo M: Adjunctive levetiracetam for treatment of refractory post-traumatic stress disorder [poster]. J Clin Psychiatry 2005, In press.
62. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL: Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998, 59:480-481.
63. Cora-Locatelli G, Greenberg BD, Martin TD, Murphy DL: Rebound psychiatric and physical symptoms after gabapentin discontinuation. J Clin Psychiatry 1998, 59:131.
64. Deltito JA: Valproate pretreatment for the difficult-to-treat patient with OCD. J Clin Psychiatry 1994, 55:500.
65. Cora-Locatelli G, Greenberg BD, Martin JD, Murphy DL: Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry 1998, 59:82.
66. Iwata Y, Kotani Y, Hoshino R, et al.: Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 2000, 61:528-529.
67. Jenike MA, Brotman AW: The EEG in obsessive-compulsive disorder. J Clin Psychiatry 1984, 45:122-124.
68. Joffe RT, Swinson RP: Carbamazepine in obsessive-compulsive disorder. Biol Psychiatry 1987, 22:1169-1171.
69. Van Ameringen M, Mancini C, Pipe B, et al.: Adjunctive topiramate in treatment resistant obsessive compulsive disorder [poster]. Presented at the 157th Annual Meeting of the American Psychiatric Association (APA). New York, May 1-6, 2004.
70. Kumar TC, Khanna S: Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 2000, 34:527-528.
71. Crane DL: Tiagabine for the treatment of anxiety [letter]. Depress Anxiety 2003, 18:51-52.
72. Schwartz TL, Ashar N, Husain J, et al.: Open-label study of tiagabine augmentation therapy for anxiety disorders [poster]. Presented at the 156th Annual Meeting of the American Psychiatric Association. San Francisco, May 17-22, 2002.
73. Worthington JJ, Kinrys G, Simon NM, et al.: Tiagabine augmentation for treatment refractory anxiety disorders [poster]. Presented at the 157th Annual Meeting of the American Psychiatric Association (APA). New York, May 1-6, 2004.
74. Kinrys G, Worthington JJ, Pardo TB, et al.: Levetiracetam as adjunctive therapy for refractory anxiety disorders [poster]. Presented at the 24th CINP Congress. Paris, June 20-24, 2004.